Immunotherapy of neuroblastoma: present, past and future

References

• Evans AE. Neuroblastoma: a historical perspective. In:Neuroblastoma, Brodeur GM, Sawada T, Tsuchida Y, Voute PA (Eds), Elsevier, NY, USA, 1–6 (2000).
   Google Scholar
• Olshan AF, Bunin GR. Epidemiology of neuroblastoma. In: Neuroblastoma, Brodeur GM, Sawada T, Tsuchida Y, Voute PA (Eds), Elsevier, NY, USA, 33–37 (2000).
   Google Scholar
• Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nature Rev. Cancer3, 203–216 (2003).
   PubMed Web of Science ®Google Scholar
• Brodeur GM, Pritchard J, Berthold F et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J. Clin. Oncol.11, 1466–1477 (1993).
   PubMed Web of Science ®Google Scholar
• Nickerson HJ, Matthay KK, Seeger RC et al. Favorable biology and outcome of Stage IV-S neuroblastoma with supportive care or minimal therapy: a Children’s Cancer Group study. J. Clin. Oncol.18, 477–486 (2000).
   PubMed Web of Science ®Google Scholar
• Weinstein JL, Katzenstein HM, Cohn, SL. Advances in the diagnosis and treatment of neuroblastoma. Oncologist 8, 278–292 (2003).
   PubMed Web of Science ®Google Scholar
• Beiske K, Ambros PF, Burchill SA, Cheung IY, Swerts K. Detecting minimal residual disease in neuroblastoma patients – the present state of the art. Cancer Lett.228, 229–40 (2005).
   PubMed Web of Science ®Google Scholar
• Seeger RC, Reynolds CP, Gallego R, Stram DO, Gerbing RB, Matthay KK. Quantitative tumor cell content of bone marrow and Blood as a predictor of outcome in Stage IV neuroblastoma: a Children’s Cancer Group Study. J. Clin. Oncol.18, 4067–4076 (2000).
   PubMed Web of Science ®Google Scholar
• Cheung IY, Sahota A, Cheung NK. Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysis. Cancer 101, 2303–2308 (2004).
   PubMed Web of Science ®Google Scholar
• Cheung IY, Lo Piccolo MS, Kushner BH, Cheung NK. Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma. J. Clin. Oncol.21, 3853–3858 (2003).
   PubMed Web of Science ®Google Scholar
• Reynolds CP. Detection and treatment of minimal residual disease in high-risk neuroblastoma. Pediatr. Transplant.8(Suppl. 5), 56–66 (2004).
   PubMed Web of Science ®Google Scholar
• Nitschke R, Parkhurst J, Sullivan J, Harris MB, Nernstein M, Pratt C. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group Phase II study. J. Pediatr. Hematol. Oncol.20, 315–318 (1998).
   PubMed Web of Science ®Google Scholar
• Saylors RL III, Stine KC, Sullivan J et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group Phase II study. J. Clin. Oncol.19, 3463–3469 (2001).
   PubMed Web of Science ®Google Scholar
• Athale U H, Stewart C, Kuttesch J F et al. Phase I study of combination topotecan and carboplatin in pediatric solid tumors. J. Clin. Oncol.20, 88–95 (2002).
   PubMed Web of Science ®Google Scholar
• Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nature Rev. Cancer1, 181–193 (2001).
   PubMed Web of Science ®Google Scholar
• Chu PW, Cheung WM, Kwong YL. Differential effects of 9-cis, 13-cis and all-trans retinoic acids on the neuronal differentiation of human neuroblastoma cells. Neuroreport 14, 1935–1939 (2003).
   PubMed Web of Science ®Google Scholar
• Matthay KK, Villablanca JG, Seeger RC et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group.N. Engl. J. Med.341, 1165–1173 (1999).
   PubMed Web of Science ®Google Scholar
• Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nature Rev. Cancer5, 231–237 (2005).
   PubMed Web of Science ®Google Scholar
• Reed JC. Apoptosis-based therapies.Nature Rev. Drug Discov.1, 111–121 (2002).
   PubMed Web of Science ®Google Scholar
• Raschellà GM, Melino G, Thiele C. Retinoids and neuroblastoma: differentiation or apoptosis? In:Neuroblastoma, Brodeur GM, Sawada T, Tsuchida Y, Voute PA (Eds), Elsevier, NY, USA, 183–191 (2000).
   Google Scholar
• Garaventa A, Luksch R, Lo Piccolo MS et al. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma.Clin. Cancer Res.9, 2032–2039 (2003).
   PubMed Web of Science ®Google Scholar
• Voute PA. Radionuclide therapy of neuroblastoma: 131I-meta-iodobenzylguanidine (MIBG). In:Neuroblastoma. Brodeur GM, Sawada T, Tsuchida Y, Voute PA (Eds), Elsevier, NY, USA, 471–476 (2000).
   Google Scholar
• Folkman J. What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Inst.82, 4–6 (1990).
   PubMed Web of Science ®Google Scholar
• Ribatti D, Vacca A, Nico B, De Falco G, Montaldo PG, Ponzoni M. Angiogenesis and anti-angiogenesis in neuroblastoma. Eur. J. Cancer38, 750–757 (2002).
   PubMed Web of Science ®Google Scholar
• Ribatti D, Surico G, Vacca A et al. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with progression in human neuroblastoma. Life Sci.68, 1161–1168 (2001).
   PubMed Web of Science ®Google Scholar
• Biagi E, Bollard C, Rousseau R, Brenner M. Gene therapy for pediatric cancer: state of the art and future perspectives. J. Biomed. Biotechnol.2003, 13–24 (2003).
   PubMedGoogle Scholar
• Bowman LC, Grossmann M, Rill D et al. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum. Gene Ther.9, 1303–1311 (1998).
   PubMed Web of Science ®Google Scholar
• Bowman L, Grossmann M, Rill D et al. IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood 92, 1941–1949 (1998).
   PubMed Web of Science ®Google Scholar
• Soling A, Schurr P, Berthold F. Expression and clinical relevance of NY-ESO-1, MAGE-1 and MAGE-3 in neuroblastoma. Anticancer Res.19, 2205–2209 (1999).
   PubMed Web of Science ®Google Scholar
• Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin. Cancer Res.10, 4307–4313 (2004).
   PubMed Web of Science ®Google Scholar
• Islam A, Kageyama H, Takada N et al. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 19, 617–623 (2000).
   PubMed Web of Science ®Google Scholar
• Lo Piccolo MS, Cheung NK, Cheung IY. GD2 synthase: a new molecular marker for detecting neuroblastoma. Cancer 92, 924–931 (2001).
   PubMed Web of Science ®Google Scholar
• Poremba C, Hero B, Heine B et al. Telomerase is a strong indicator for assessing the proneness to progression in neuroblastomas. Med. Pediatr. Oncol.35, 651–655 (2000).
   PubMedGoogle Scholar
• Sarkar AK, Nuchtern JG. Lysis of MYCN-amplified neuroblastoma cells by MYCN peptide-specific cytotoxic T lymphocytes. Cancer Res.60, 1908–1913 (2000).
   PubMed Web of Science ®Google Scholar
• Passoni L, Scardino A, Bertazzoli C et al. ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes. Blood 99, 2100–2106 (2002).
   PubMed Web of Science ®Google Scholar
• Coughlin CM, Vance BA, Grupp SA, Vonderheide RH. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy.Blood 103, 2046–2054 (2004).
   PubMed Web of Science ®Google Scholar
• Rodolfo M, Luksch R, Stockert E et al. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen. Cancer Res.63, 6948–6955 (2003).
   PubMed Web of Science ®Google Scholar
• Raffaghello L, Marinpietri D, Pagnan G et al. Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse. Cancer Lett.197, 205–209 (2003).
   PubMed Web of Science ®Google Scholar
• Krause A, Guo HF, Latouche JB, Tan C, Cheung NK, Sadelain M. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J. Exp. Med. 188, 619–626 (1998).
   PubMed Web of Science ®Google Scholar
• Lampson LA, Fisher, CA, Whelan JP. Striking paucity of HLA-A, B, C and β2-microglobulin on human neuroblastoma cell lines. J. Immunol.130, 2471–2478 (1983).
   PubMed Web of Science ®Google Scholar
• Corrias MV, Occhino M, Croce M et al. Lack of HLA-class I antigens in human neuroblastoma cells: analysis of its relationship to TAP and tapasin expression. Tissue Antigens57, 110–117 (2001).
   PubMedGoogle Scholar
• Raffaghello L, Prigione I, Bocca P et al. Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene 24, 4634–4644 (2005).
   PubMed Web of Science ®Google Scholar
• Raffaghello L, Prigione I, Airoldi I et al. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 6, 558–568 (2004).
   PubMed Web of Science ®Google Scholar
• Raffaghello L, Prigione I, Airoldi I et al. Mechanisms of immune evasion of human neuroblastoma. Cancer Lett.228, 155–161 (2005).
   PubMed Web of Science ®Google Scholar
• Castriconi R, Dondero A, Augugliaro R et al. Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc. Natl Acad. Sci. USA 101, 12640–12645 (2004).
   PubMed Web of Science ®Google Scholar
• Mujoo K, Cheresh DA, Yang HM, Reisfeld RA. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res.47, 1098–1104 (1987).
   PubMed Web of Science ®Google Scholar
• Cheung NK, AL Yu. Immunotherapy of neuroblastoma. In: Neuroblastoma, Brodeur GM, Sawada T, Tsuchida Y, Voute PA (Eds), Elsevier, NY, USA, 541–549 (2000).
   Google Scholar
• Uttenreuther-Fischer MM, Huang CS, Reisfeld RA, Yu AL. Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a Phase I trial in pediatric cancer patients.Cancer Immunol. Immunother.41, 29–36 (1995).
   PubMed Web of Science ®Google Scholar
• Cheung NK, Kushner BH, LaQuaglia M et al. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.Med. Pediatr. Oncol.36, 227–230 (2001).
   PubMedGoogle Scholar
• Murray JL, Cunningham JE, Brewer H et al. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J. Clin. Oncol.12, 184–193 (1994).
   PubMed Web of Science ®Google Scholar
• Yu AL, Uttenreuther-Fischer MM, Huang CS et al. Phase I trial of a human–mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J. Clin. Oncol.16, 2169–2180 (1998).
   PubMed Web of Science ®Google Scholar
• Kushner BH, Kramer K, Modak S, Cheung NK. Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma. Clin. Cancer Res.10, 84–87 (2004).
   PubMed Web of Science ®Google Scholar
• Kushner BH, Kramer K, Cheung NK. Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J. Clin. Oncol.19, 4189–4194 (2001).
   PubMed Web of Science ®Google Scholar
• Frost JD, Hank JA, Reaman GH et al. A Phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children’s Cancer Group. Cancer 80, 317–333 (1997).
   PubMed Web of Science ®Google Scholar
• Modak S, Cheung NK. Antibody-based targeted radiation to pediatric tumors.J. Nucl. Med.46(Suppl. 1), 157S–163S (2005).
   PubMed Web of Science ®Google Scholar
• Sen G, Chakraborty M, Foon KA, Reisfeld RA, Bhattacharya-Chatterjee M. Preclinical evaluation in nonhuman primates of murine monoclonal anti-idiotype antibody that mimics the disialoganglioside GD2. Clin. Cancer Res.3, 1969–1976 (1997).
   PubMed Web of Science ®Google Scholar
• Cheung NK, Guo HF, Cheung IY. Correlation of anti-idiotype network with survival following anti-G(D2) monoclonal antibody 3F8 therapy of stage 4 neuroblastoma. Med. Pediatr. Oncol.35, 635–637 (2000).
   PubMedGoogle Scholar
• Cheung NK, Guo HF, Heller G, Cheung IY. Induction of Ab3 and Ab3´ antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma. Clin. Cancer Res.6, 2653–2660 (2000).
   PubMed Web of Science ®Google Scholar
• Bolesta E, Kowalczyk A, Wierzbicki A. et al. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses. Cancer Res.65, 3410–6418 (2005).
   PubMed Web of Science ®Google Scholar
• Cheung NK, Modak S. Oral (1 > 3),(1 > 4)-β-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin. Cancer. Res.8, 1217–1223 (2002).
   PubMed Web of Science ®Google Scholar
• Pession A, Prete A, Locatelli F et al. Immunotherapy with low-dose recombinant interleukin 2 after high-dose chemotherapy and autologous stem cell transplantation in neuroblastoma. Br. J. Cancer78, 528–533 (1998).
   PubMed Web of Science ®Google Scholar
• Michon J, Moutel S, Barbet J et al.In vitro killing of neuroblastoma cells by neutrophils derived from granulocyte colony-stimulating factor-treated cancer patients using an anti-disialoganglioside/anti-Fc γ RI bispecific antibody. Blood 86, 1124–1130 (1995).
   PubMed Web of Science ®Google Scholar
• Rapoport AP, Stadtmauer EA, Aqui N et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nature Med.11, 1230–1237 (2005).
   PubMed Web of Science ®Google Scholar
• Lode HN, Xiang R, Varki NM, Dolman CS, Gillies SD, Reisfeld RA. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.J. Natl Cancer Inst.89, 1586–1594 (1997).
   PubMed Web of Science ®Google Scholar
• King DM, Albertini M R, Schalch H et al. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J. Clin. Oncol.22, 4463–4473 (2004).
   PubMed Web of Science ®Google Scholar
• Morse MA, Chui S, Hobeika A, Lyerly HK, Clay T. Recent developments in therapeutic cancer vaccines. Nature Clin. Pract. Oncol.2, 108–113 (2005).
   PubMedGoogle Scholar
• Geiger JD, Hutchinson RJ, Hohenkirk LF et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res.61, 8513–8519 (2001).
   PubMed Web of Science ®Google Scholar
• Caruso DA, Orme LM, Amor G M et al. Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with stage 4 neuroblastoma. Cancer 103, 1280–1291 (2005).
   PubMed Web of Science ®Google Scholar
• Zeng Y, Jiang J, Huebener N et al. Fractalkine gene therapy for neuroblastoma is more effective in combination with targeted IL-2. Cancer Lett.228, 187–193 (2005).
   PubMed Web of Science ®Google Scholar
• Croce M, Meazza R, Orengo AM et al. Sequential immunogene therapy with interleukin-12- and interleukin-15-engineered neuroblastoma cells cures metastatic disease in syngeneic mice. Clin. Cancer Res.11, 735–742 (2005).
   PubMed Web of Science ®Google Scholar
• Castriconi R, Dondero A, Corrias MV et al. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res.64, 9180–9184 (2004).
   PubMed Web of Science ®Google Scholar
• Valteau-Couanet D, Benhamou E, Vassal G et al. Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma. Bone Marrow Transplant25, 937–942 (2000).
   PubMed Web of Science ®Google Scholar